Latest Breaking News On - William muller - Page 16 : comparemela.com
Hombre muere tras ser atropellado por un camión en esquina de Picarte con Pedro Montt en Valdivia | Nacional
biobiochile.cl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biobiochile.cl Daily Mail and Mail on Sunday newspapers.
【未解之謎】捕捉靈魂的攝影師
ntdtv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ntdtv.com Daily Mail and Mail on Sunday newspapers.
Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Nirsevimab Phase III trial met primary endpoint
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial
Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants.
1
5
Nirsevimab is being investigated as a first-in-class single dose immunization to provide protection for all infants entering their first RSV season.
Nirsevimab met its Phase 3 primary endpoint earlier than anticipated; regulatory submissions for all-infant indication to begin in 2022.
PARIS
– April 26, 2021 – Positive topline results from the Phase 3 MELODY trial showed nirsevimab reduced lower respiratory tract infections (LRTI) requiring medical attention (inpatient or outpatient) due to respiratory syncytial virus (RSV) in healthy preterm and term infants. RSV is the most common cause of LRTI and the leading cause of hospitalizations in all infants.
Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.